Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL
In this MEDtalk, MD and Assistant Professor Paolo Strati present findings from the first-ever clinical trial testing anti-signal regulatory protein-alpha (SIRPα) antibody CC-95251 in combination with Rituximab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
